... ablation with consecutive risks including osteoporosis and pathologic fractures. A recent randomized trial found that the RANK ligand inhibitor denosumab was more effective preventing skeletal-related events in patients with metastatic PCa as compared to treatment with the bisphosphonate zoledronic acid...

..., docetaxel and zoledronic acid combination in CRPC. Patients and Methods: Thirty patients were enrolled to receive calcitriol 0.5 µg/kg orally in 4 divided doses over 4 h on day 1 of each treatment week, docetaxel 36 mg/m 2 i.v. infusion on day 2 of each treatment week and zoledronic acid 4 mg i.v. on day 2...

... of CRPC. By inhibiting the pathologic processes of osteoclast-mediated bone resorption, bisphosphonates (BPs) can potentially reduce bone pain in patients with metastatic bone disease [ 8 ]. According to the most recent EAU guidelines on the management of PCa, the application of zoledronic acid (ZA...